Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Autor: | Ueda, Peter, Svanström, Henrik, Melbye, Mads, Eliasson, Björn, Svensson, Ann-Marie, Franzén, Stefan, Gudbjörnsdottir, Soffia, Hveem, Kristian, Jonasson, Christian, Pasternak, Björn |
---|---|
Předmět: |
DRUG side effects
ACUTE kidney failure CONFIDENCE intervals DIABETIC acidosis REPORTING of diseases BONE fractures LEG amputation LONGITUDINAL method PANCREATITIS THROMBOEMBOLISM URINARY tract infections VEINS DISEASE incidence PROPORTIONAL hazards models SODIUM-glucose cotransporters GLUCAGON-like peptide-1 agonists ODDS ratio CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN |
Zdroj: | BMJ: British Medical Journal; 11/17/2018, Vol. 363 Issue 8176, pk4365-10, 10p, 1 Diagram, 4 Charts |
Databáze: | Complementary Index |
Externí odkaz: |